FI109453B - Farmaseuttinen koostumus - Google Patents

Farmaseuttinen koostumus Download PDF

Info

Publication number
FI109453B
FI109453B FI991485A FI991485A FI109453B FI 109453 B FI109453 B FI 109453B FI 991485 A FI991485 A FI 991485A FI 991485 A FI991485 A FI 991485A FI 109453 B FI109453 B FI 109453B
Authority
FI
Finland
Prior art keywords
pharmaceutically acceptable
carbidopa
entacapone
levodopa
mixture
Prior art date
Application number
FI991485A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI991485L (fi
FI991485A0 (fi
Inventor
Kari Vahervuo
Sari Kallioinen
Lasse Kervinen
Marja Laaksonen
Jarmo Lintulaakso
Mervi Niskanen
Marja Partanen
Marja Ritala
Matti Virkki
Original Assignee
Orion Yhtymae Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI109453(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Yhtymae Oyj filed Critical Orion Yhtymae Oyj
Priority to FI991485A priority Critical patent/FI109453B/fi
Publication of FI991485A0 publication Critical patent/FI991485A0/fi
Priority to TW089110218A priority patent/TWI241187B/zh
Priority to PE2000000641A priority patent/PE20010399A1/es
Priority to IT2000MI001450A priority patent/ITMI20001450A1/it
Priority to CO00048944A priority patent/CO5180579A1/es
Priority to GE4619A priority patent/GEP20043314B/en
Priority to EP00944070A priority patent/EP1189608B1/en
Priority to ES00944070T priority patent/ES2203495T3/es
Priority to JP2001507476A priority patent/JP4204783B2/ja
Priority to DE60004052T priority patent/DE60004052T2/de
Priority to ARP000103325A priority patent/AR033796A1/es
Priority to MYPI20002972A priority patent/MY127685A/en
Priority to DK00944070T priority patent/DK1189608T3/da
Priority to HK02108609.4A priority patent/HK1047040B/zh
Priority to CZ20014636A priority patent/CZ303010B6/cs
Priority to NZ515780A priority patent/NZ515780A/en
Priority to EEP200100716A priority patent/EE05473B1/xx
Priority to CA002378469A priority patent/CA2378469C/en
Priority to AT00944070T priority patent/ATE245417T1/de
Priority to TR2001/03763T priority patent/TR200103763T2/xx
Priority to MEP-2008-863A priority patent/ME00520B/me
Priority to KR1020017015737A priority patent/KR100905428B1/ko
Priority to CZ2011-885A priority patent/CZ304416B6/cs
Priority to HU0202273A priority patent/HU230395B1/hu
Priority to US09/605,529 priority patent/US6500867B1/en
Priority to AU58306/00A priority patent/AU765932B2/en
Priority to SI200030190T priority patent/SI1189608T1/xx
Priority to HR20020088A priority patent/HRP20020088B1/xx
Priority to UA2002010771A priority patent/UA75047C2/uk
Priority to BR0011867-2A priority patent/BR0011867A/pt
Priority to SK1923-2001A priority patent/SK286451B6/sk
Priority to PCT/FI2000/000593 priority patent/WO2001001984A1/en
Priority to PT00944070T priority patent/PT1189608E/pt
Priority to CNB008095868A priority patent/CN1168440C/zh
Priority to BRPI0011867A priority patent/BRPI0011867B8/pt
Priority to MXPA01013167A priority patent/MXPA01013167A/es
Priority to EA200200106A priority patent/EA004503B1/ru
Priority to PL352775A priority patent/PL197818B1/pl
Priority to YUP-925/01A priority patent/RS50368B/sr
Priority to FR0008472A priority patent/FR2797587A1/fr
Publication of FI991485L publication Critical patent/FI991485L/fi
Priority to ZA200109868A priority patent/ZA200109868B/xx
Priority to IL146807A priority patent/IL146807A/en
Priority to NO20016203A priority patent/NO330260B1/no
Priority to BG106251A priority patent/BG65364B1/bg
Application granted granted Critical
Publication of FI109453B publication Critical patent/FI109453B/fi
Priority to US10/223,298 priority patent/US6797732B2/en
Priority to JP2008063280A priority patent/JP4885896B2/ja
Priority to NO20110090A priority patent/NO20110090L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
FI991485A 1999-06-30 1999-06-30 Farmaseuttinen koostumus FI109453B (fi)

Priority Applications (47)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus
TW089110218A TWI241187B (en) 1999-06-30 2000-05-26 Levodopa/carbidopa/entacapone pharmaceutical composition
PE2000000641A PE20010399A1 (es) 1999-06-30 2000-06-27 Composicion solida oral que contiene entacapona, levodopa y carbidopa
IT2000MI001450A ITMI20001450A1 (it) 1999-06-30 2000-06-28 Nuova composizione farmaceutica
HU0202273A HU230395B1 (hu) 1999-06-30 2000-06-29 Levodopa /carbidopa/ entacapone tartalmú orálisan adagolható szilárd készítmény, eljárás ennek előállítására és ezt tartalmazó tabletta
HR20020088A HRP20020088B1 (hr) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmaceutski pripravak
EP00944070A EP1189608B1 (en) 1999-06-30 2000-06-29 Levodopa/carbidopa/entacapone pharmaceutical preparation
ES00944070T ES2203495T3 (es) 1999-06-30 2000-06-29 Preparado farmaceutico de levodopa/carbidopa/entacapona.
JP2001507476A JP4204783B2 (ja) 1999-06-30 2000-06-29 レボドパ/カルビドパ/エンタカポン医薬製剤
DE60004052T DE60004052T2 (de) 1999-06-30 2000-06-29 Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone
ARP000103325A AR033796A1 (es) 1999-06-30 2000-06-29 Composicion farmaceutica
MYPI20002972A MY127685A (en) 1999-06-30 2000-06-29 Levodopa/carbidopa/entacapone pharmaceutical preparation
DK00944070T DK1189608T3 (da) 1999-06-30 2000-06-29 Farmaceutisk fremstilling på basis af levodopa, carbidopa og entacapon
HK02108609.4A HK1047040B (zh) 1999-06-30 2000-06-29 左旋多巴/卡比多巴/恩他卡朋藥物製劑
CZ20014636A CZ303010B6 (cs) 1999-06-30 2000-06-29 Perorální pevná kompozice obsahující entacapon, levodopu a karbidopu, zpusoby její prípravy a použití
NZ515780A NZ515780A (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation
EEP200100716A EE05473B1 (et) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapooni farmatseutiline preparaat, selle valmistamise meetod ja kasutamine
CA002378469A CA2378469C (en) 1999-06-30 2000-06-29 An oral solid composition comprising carbidopa, levodopa and entacapone
AT00944070T ATE245417T1 (de) 1999-06-30 2000-06-29 Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone
TR2001/03763T TR200103763T2 (tr) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmasötik preparasyonu.
MEP-2008-863A ME00520B (me) 1999-06-30 2000-06-29 Levodop/karbidop/entakapon farmaceutski preparat
KR1020017015737A KR100905428B1 (ko) 1999-06-30 2000-06-29 레보도파/카비도파/엔타카폰 약학적 제제
CZ2011-885A CZ304416B6 (cs) 1999-06-30 2000-06-29 Farmaceutická kompozice obsahující entacapon, levodopu a karbidopu a léčivo pro léčení Parkinsonovy choroby
CO00048944A CO5180579A1 (es) 1999-06-30 2000-06-29 Composicion oral solida que comprende levidopa, carbidopa y entacapone
US09/605,529 US6500867B1 (en) 1999-06-30 2000-06-29 Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
AU58306/00A AU765932B2 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation
SI200030190T SI1189608T1 (en) 1999-06-30 2000-06-29 Levodopa/carbidopa/entacapone pharmaceutical preparation
GE4619A GEP20043314B (en) 1999-06-30 2000-06-29 Pharmaceutical Composition Comprising Entacapone, Levodopa, and Carbidopa
UA2002010771A UA75047C2 (en) 1999-06-30 2000-06-29 Fixed dose composition of levodopa, carbidopa and entacapone
BR0011867-2A BR0011867A (pt) 1999-06-30 2000-06-29 Preparação farmacêutica de levodopa/carbidopa/entacapona
SK1923-2001A SK286451B6 (sk) 1999-06-30 2000-06-29 Perorálna pevná kompozícia obsahujúca entakapon, levodopu a karbidopu a spôsoby jej prípravy a použitie
PCT/FI2000/000593 WO2001001984A1 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation
PT00944070T PT1189608E (pt) 1999-06-30 2000-06-29 Preparacao farmaceutica de levodopa/carbidopa/entacapona
CNB008095868A CN1168440C (zh) 1999-06-30 2000-06-29 左旋多巴/卡比多巴/恩他卡朋药物制剂
BRPI0011867A BRPI0011867B8 (pt) 1999-06-30 2000-06-29 preparação farmacêutica de levodopa/carbidopa/entacapona e processo para preparação da mesma
MXPA01013167A MXPA01013167A (es) 1999-06-30 2000-06-29 Preparacion farmaceutica de levodopa / carbidopa / entacapona.
EA200200106A EA004503B1 (ru) 1999-06-30 2000-06-29 Фармацевтическая композиция леводопа/карбидопа/энтакапон
PL352775A PL197818B1 (pl) 1999-06-30 2000-06-29 Stałe doustne kompozycje lewodopa/karbidopa/entakapon, sposób ich wytwarzania oraz ich zastosowanie
YUP-925/01A RS50368B (sr) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmaceutski preparat
FR0008472A FR2797587A1 (fr) 1999-06-30 2000-06-30 Nouvelle composition pharmaceutique
ZA200109868A ZA200109868B (en) 1999-06-30 2001-11-29 Levodopa/carbidopa/entacapone pharmaceutical preparation.
IL146807A IL146807A (en) 1999-06-30 2001-11-29 Levodopa/carbidopa/entacapone pharmaceutical preparation
NO20016203A NO330260B1 (no) 1999-06-30 2001-12-18 Oral, fast sammensetning omfattende levodopa/carbidopa/entacapon, fremgangsmate for fremstilling derav, samt anvendelse av en sammensetning omfattende levodopa/carbidopa/entacapon for fremstilling av et medikament til behandling av Parkinsons sykdom.
BG106251A BG65364B1 (bg) 1999-06-30 2001-12-20 Фармацевтичен препарат леводопа/карбидопа/ентакапон
US10/223,298 US6797732B2 (en) 1999-06-30 2002-08-20 Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
JP2008063280A JP4885896B2 (ja) 1999-06-30 2008-03-12 レボドパ/カルビドパ/エンタカポン医薬製剤
NO20110090A NO20110090L (no) 1999-06-30 2011-01-19 Stabil fast oral sammensetning omfattende levodopa, carbidopa, og entacapon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991485 1999-06-30
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus

Publications (3)

Publication Number Publication Date
FI991485A0 FI991485A0 (fi) 1999-06-30
FI991485L FI991485L (fi) 2000-12-31
FI109453B true FI109453B (fi) 2002-08-15

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus

Country Status (42)

Country Link
US (2) US6500867B1 (cs)
EP (1) EP1189608B1 (cs)
JP (2) JP4204783B2 (cs)
KR (1) KR100905428B1 (cs)
CN (1) CN1168440C (cs)
AR (1) AR033796A1 (cs)
AT (1) ATE245417T1 (cs)
AU (1) AU765932B2 (cs)
BG (1) BG65364B1 (cs)
BR (2) BR0011867A (cs)
CA (1) CA2378469C (cs)
CO (1) CO5180579A1 (cs)
CZ (2) CZ303010B6 (cs)
DE (1) DE60004052T2 (cs)
DK (1) DK1189608T3 (cs)
EA (1) EA004503B1 (cs)
EE (1) EE05473B1 (cs)
ES (1) ES2203495T3 (cs)
FI (1) FI109453B (cs)
FR (1) FR2797587A1 (cs)
GE (1) GEP20043314B (cs)
HK (1) HK1047040B (cs)
HR (1) HRP20020088B1 (cs)
HU (1) HU230395B1 (cs)
IL (1) IL146807A (cs)
IT (1) ITMI20001450A1 (cs)
ME (1) ME00520B (cs)
MX (1) MXPA01013167A (cs)
MY (1) MY127685A (cs)
NO (2) NO330260B1 (cs)
NZ (1) NZ515780A (cs)
PE (1) PE20010399A1 (cs)
PL (1) PL197818B1 (cs)
PT (1) PT1189608E (cs)
RS (1) RS50368B (cs)
SI (1) SI1189608T1 (cs)
SK (1) SK286451B6 (cs)
TR (1) TR200103763T2 (cs)
TW (1) TWI241187B (cs)
UA (1) UA75047C2 (cs)
WO (1) WO2001001984A1 (cs)
ZA (1) ZA200109868B (cs)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
EP1560569A4 (en) * 2002-10-11 2006-03-22 Depomed Dev Ltd GASTRORETENTIVE LEVODOPA DELIVERY FORM
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20060241183A1 (en) * 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
CA2611114C (en) * 2005-06-08 2014-09-23 Orion Corporation An entacapone-containing oral dosage form
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
US8168793B2 (en) * 2005-07-26 2012-05-01 Portela & Ca., S.A. Nitrocatechol derivatives as COMT inhibitors
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
EP1948153A2 (en) * 2005-09-21 2008-07-30 Orion Corporation Treatment of symptoms of parkinson`s disease
EP1945188A2 (en) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa compositions
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008053297A2 (en) * 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
EP2063867A2 (en) * 2006-12-22 2009-06-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
US8524746B2 (en) 2007-01-31 2013-09-03 Bial-Portela & Ca., S.A. Dosage regimen for COMT inhibitors
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
BRPI0907727A2 (pt) * 2008-02-06 2017-06-13 Wockhardt Res Centre composições farmacêuticas de entacapone co-micronizado com alcoóis de açúcar
KR101444979B1 (ko) * 2008-02-06 2014-10-07 욱크하르트 리미티드 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물
JP2011514380A (ja) 2008-03-17 2011-05-06 バイアル−ポルテラ アンド シーエー,エス.エー. 5−[3−(2,5−ジクロロ−4,6−ジメチル−1−オキシ−ピリジン−3−イル)[1,2,4]オキサジアゾール−5−イル]−3−ニトロベンゼン−1,2−ジオールの結晶形
CA2734972C (en) * 2008-08-22 2017-03-28 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
WO2010020970A1 (en) * 2008-08-22 2010-02-25 Wockhardt Research Centre Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20120027197A (ko) 2009-04-01 2012-03-21 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
PL2432454T3 (pl) * 2009-05-19 2017-10-31 Neuroderm Ltd Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
JP5718937B2 (ja) 2009-12-25 2015-05-13 イノファーマックス インコーポレイテッド パーキンソン病を治療するための医薬組成物及びその調製方法
WO2011107653A2 (en) 2010-03-04 2011-09-09 Orion Corporation Method for treating parkinson's disease
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
PT3326615T (pt) * 2010-11-15 2020-03-23 Neuroderm Ltd Administração continua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
US20140120166A1 (en) * 2011-04-26 2014-05-01 Innopharmax, Inc. Composition of entacopone
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
WO2013183055A1 (en) 2012-06-05 2013-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
ES2889626T3 (es) * 2013-03-13 2022-01-12 Neuroderm Ltd Combinación para el tratamiento de la enfermedad de Parkinson
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP6506271B2 (ja) 2013-10-07 2019-04-24 インパックス ラボラトリーズ、 インコーポレイテッドImpax Laboratories, Inc. レボドパ及び/又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PL3782617T3 (pl) 2014-09-04 2024-06-24 Lobsor Pharmaceuticals Aktiebolag Farmaceutyczne kompozycje żelowe zawierające lewodopę, karbidopę i entakapon
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ,エス.アー. パーキンソン病を遅延させるための医薬
WO2016101969A1 (en) 2014-12-23 2016-06-30 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
AU2017297718B2 (en) * 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
WO2018034626A1 (en) 2016-08-18 2018-02-22 İlko İlaç Sanayi Ve Ticaret Anonim Şirketi Antiparkinson tablet formulation with improved dissolution profile
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
SG11202009215PA (en) 2018-03-23 2020-10-29 Lobsor Pharmaceuticals Ab Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
CZ303010B6 (cs) 2012-02-29
FI991485L (fi) 2000-12-31
ES2203495T3 (es) 2004-04-16
ATE245417T1 (de) 2003-08-15
JP2003503454A (ja) 2003-01-28
AU5830600A (en) 2001-01-22
HRP20020088B1 (hr) 2007-05-31
KR20020010155A (ko) 2002-02-02
NO20016203L (no) 2002-02-25
TWI241187B (en) 2005-10-11
US6500867B1 (en) 2002-12-31
EA004503B1 (ru) 2004-04-29
NO20016203D0 (no) 2001-12-18
CZ20014636A3 (cs) 2002-05-15
FI991485A0 (fi) 1999-06-30
DE60004052T2 (de) 2004-04-15
KR100905428B1 (ko) 2009-06-30
EP1189608B1 (en) 2003-07-23
JP4204783B2 (ja) 2009-01-07
CN1358090A (zh) 2002-07-10
CZ304416B6 (cs) 2014-04-23
MXPA01013167A (es) 2002-07-02
CA2378469A1 (en) 2001-01-11
EE200100716A (et) 2003-02-17
BG65364B1 (bg) 2008-04-30
NZ515780A (en) 2004-06-25
BG106251A (en) 2002-08-30
NO20110090L (no) 2002-02-25
CA2378469C (en) 2009-10-06
NO330260B1 (no) 2011-03-14
CO5180579A1 (es) 2002-07-30
EP1189608A1 (en) 2002-03-27
HUP0202273A3 (en) 2002-11-28
AU765932B2 (en) 2003-10-02
ME00520B (me) 2011-10-10
SK286451B6 (sk) 2008-10-07
SI1189608T1 (en) 2004-04-30
DE60004052D1 (de) 2003-08-28
YU92501A (sh) 2004-09-03
HUP0202273A2 (en) 2002-10-28
RS50368B (sr) 2009-11-10
PT1189608E (pt) 2003-12-31
BRPI0011867B1 (pt) 2019-01-08
ZA200109868B (en) 2003-05-28
HK1047040B (zh) 2005-04-29
ITMI20001450A1 (it) 2001-12-28
BRPI0011867B8 (pt) 2021-05-25
PL197818B1 (pl) 2008-04-30
TR200103763T2 (tr) 2002-04-22
FR2797587A1 (fr) 2001-02-23
BR0011867A (pt) 2002-03-05
JP4885896B2 (ja) 2012-02-29
US20030017201A1 (en) 2003-01-23
HRP20020088A2 (en) 2005-10-31
MY127685A (en) 2006-12-29
UA75047C2 (en) 2006-03-15
EE05473B1 (et) 2011-10-17
HK1047040A1 (en) 2003-02-07
CN1168440C (zh) 2004-09-29
PE20010399A1 (es) 2001-04-10
JP2008156373A (ja) 2008-07-10
EA200200106A1 (ru) 2002-06-27
US6797732B2 (en) 2004-09-28
WO2001001984A1 (en) 2001-01-11
PL352775A1 (en) 2003-09-08
AR033796A1 (es) 2004-01-07
DK1189608T3 (da) 2003-11-10
HU230395B1 (hu) 2016-04-28
IL146807A (en) 2006-10-05
GEP20043314B (en) 2004-02-10
SK19232001A3 (sk) 2002-06-04
ITMI20001450A0 (it) 2000-06-28

Similar Documents

Publication Publication Date Title
FI109453B (fi) Farmaseuttinen koostumus
US8741342B2 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
CA2465110A1 (en) Tamsulosin tablets
CA2696977C (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
US20090292016A1 (en) Stable Pharmaceutical Compositions Containing Pravastatin
US7959948B2 (en) Pharmaceutical composition of quetiapine fumarate
EP2471520B1 (en) Pharmaceutical compositions of levetiracetam
KR20090021222A (ko) 수분 민감성 약물 및 제2 약물의 배합을 포함하는 안정한 제제 및 이의 제조 방법

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ORION CORPORATION

Free format text: ORION CORPORATION

MA Patent expired